There is an increasing body of data showing that activated cancer therapy-the synergistic effect of "preloaded" molecules and a tuned energy source to produce cytopathogenic moieties-is a promising new modality for cancer treatment. The key activated therapies are photodynamic therapy (PDT), which involves the synergy between light and photosensitizer molecules, and ultrasound activated therapy (USAT; also referred to as sonodynamic therapy), which involves the synergy between ultrasound and sonosensitizer molecules. PDT is a well-known activated therapy with roots dating back to 1900. However, minimal data exist on USAT. One reason is the lack of suitable sonosensitizers for clinical USAT use. The authors present both LC 50 toxicity and cancer cell cytotoxicity studies on 2 dual activation agents. These compounds function as both sonosensitizers and photosensitizers, and are referred to as SonneLux agents, designated SF1 and SF2. The sensitizers are derived from chlorophyll and are metal centered porphyrins known to specifically accumulate in hyperproliferating tissue. LC 50 studies on both SF1 and SF2 as determined in zebra fish reveal that both are essentially nontoxic to zebra fish. In the worst case, 5% zebra fish death is noted at the maximum soluble concentration of the sensitizer. In the cytotoxicity studies, melanoma cell line WM-266-4, derived from a metastatic site of a malignant melanoma, was tested against SF1 and SF2. Both sensitizer systems showed marked efficacy in the destruction of the implanted melanoma cells. They show great promise for clinical use in the future.
Introduction
There are increasing data showing that activated cancer therapy (ACT), which refers to a synergistic interaction of molecules and a tuned energy source to produce cytopatho genic moieties, is a promising new modality for cancer treatment. 1, 2 The key activated therapies are the following: photodynamic therapy (PDT), which involves the synergy between light and photosensitizer molecules, and ultrasound activated therapy (USAT, also referred to as sonodynamic therapy), which involves the synergy between ultrasound and sonosensitizer molecules. USAT has recently been shown to overcome some of the limitations of PDT. 3, 4 Activation of a photosensitizer req uires light, which has limited ability to penetrate tissue. Red light, as an activator, is able to penetrate up to 1 cm in depth into the body. Lightbearing catheters provide an option for treating deepseated tumors. 5, 6 Ultrasound is able to penetrate through tissue and activate a sonosensitizer embedded in tumor tissue deep in the body. 4, 7 In addition, sonosensitizers are often less photoactive and, thus, are less photosensitizing to the skin of patients. 8 Although USAT shows enhanced potential compared with PDT, there is a paucity of clinical data on USAT. One reason is the lack of suitable sonosensi tizers for clinical USAT use.
Reported here is a new series of sensitizing agents ref erred to as SonneLux. These compounds have been shown to be activated by red light or ultrasound and thus are referred to as dualactivation sensitizers. The SonneLux agents (SF1 and SF2) are analogs of chlorophyll in that their macrocycle backbone is porphyrin based, and the center of the porphyrin ring is populated with a metal ion. Porphyrins have been suggested to be useful as photosen sitizers and sonosensitizers in activated therapy in oncology and other disease states. 925 In ACT, a sensitizer compound that demonstrates the ability to selectively accumulate in target tissue, such as neoplastic or hyperproliferative tissue, is administered to a patient, and when the sensitizer accu mulates in or preferentially associates with the target tissue, the target tissue becomes sensitized to electromagnetic radiation. The photosensitizing agent can be activated either by coherent (laser) or noncoherent (nonlaser) light, whereas the sonosensitizing agent can be activated by ultrasound.
It is currently accepted that following absorption of light, photosensitizers are transformed from the ground singlet state (P) into an electronically excited triplet state ( 3 P*; T ~ 10 -2 s) via a shortlived excited singlet state ( 1 P*; T ~ 10 -6 s). The excited triplet can undergo nonradiative decay or partici pate in an electron transfer process with biological substrates to form radicals and radical ions, which can produce singlet oxygen and superoxide (O 2 -) after interaction with molecular oxygen (O 2 ). 2633 Singlet oxygen can be produced from mole cular oxygen by the transfer of energy directly or indirectly from the activated photosensitizer. Singlet oxygen is one of the agents responsible for cellular and tissue damage in PDT, causing oxidation of the target tissue; there is also evidence that the superoxide ion may be involved. 34 The generation of these cytopathogenic agents plays a role in tumor homeosta sis and the observed tumor destruction. 35 The mechanism for the creation of ultrasoundactivated cytopathogenic moieties is not completely understood but is theorized to be similar to that of the photodynamic effect. 27 The downstream mechanisms of action are postulated to be freeradical formation, 36, 37 cavitation, 3840 and sonopora tion. 41, 42 Ultrasonically induced cell damage via freeradical generation is supported by various studies suggesting that active oxygen radical generation 37 and peroxyl radical for mation 36 are responsible for cell damage during the ultrasound activation of the sensitizer compounds. The synergistic cell killing effect of ultrasound and porphyrin derivatives 40 might be mediated through cavitationrelated high temperatures within the microbubble itself, 43 contributing to thermal des truction of the cancer cell, a unique feature of sonodynamic therapy. Sonoporation 42 is a process by which chain peroxi dation of membrane lipids destabilizes the cell membrane with the sonosensitizers and can therefore cause tumor cells to be more susceptible to drug transport of cancerfighting compounds through the cell membrane. There also appears to be less dissolved oxygen concentration dependence in USAT compared with PDT. 44 In a previous publication in this journal, we presented the effect of USAT with SF1 on S180 sarcoma in mice. 4 Tumor growth inhibition was seen, and with increasing ultrasound intensity, the inhibitive effect was enhanced. Pathological slices showed coagulated necrosis or metamorphic tissue with inflammatory reaction in the tumor taken from 2 hours to 36 hours after USAT. These data revealed that USAT with SF1 did inhibit growth of mouse S180 sarcoma and that the inhibitive effect was dependent on sound intensity.
USAT also induced inflammation while it destroyed the tumor, indicative of a "vaccine" effect. 4, 45 Continued study and advancement of ACT is critical because of the vast potential of this therapeutic concept to treat cancer and other diseases. Some of the emerging benefits of activated therapy 46, 47 over conventional cancer treatments are discussed below.
Efficacy
USAT shows remarkable ability to destroy malignant tissue causing necrosis, apoptosis, 48 destruction of neovascular networks, and an inflammatory vaccine effect 4, 45 and may also destroy the antecedents of cancer, including viruses and bacteria. 4951
Ability to Treat a Wide Range of Solid Tumor Cancers
USAT overcomes limitations of PDT, mainly that the energy source, often red light, cannot penetrate beyond about 1 cm into the body. Ultrasound is able to penetrate through the body and activate the sonosensitizer. USAT has shown promise in treating gliomas; thus, the ultrasound penetrates through the skull, and the sensitizer passes through the bloodbrain barrier. 52, 53 
Quality of Life
Activated therapy with the new generation of sensitizers has a high therapeutic index, is noninvasive, and is well toler ated by patients. Much of the side effects are attributable to the destruction of cancer cells-not to the sensitizers or the energy source. Side effects are effectively managed by con trolling the rate of tumor cell destruction.
Aesthetics
Aggressive treatment with radiation often results in unaccept able damage to underlying tissue. Excellent cosmetic outcome with activated therapy makes it important in skin lesions and cancer of the head and neck where preserving function and respecting delicate underlying structures is critical. 54, 55 Specificity New sensitizers have high specificity for tumor tissue. Many of the new compounds not only become cytotoxic when an energy source is supplied but also fluoresce when irradiated with the proper wavelength of light. Using this feature, researchers and physicians have been able to map out the concentration gradients and partition ing of sensitizers in healthy and cancerous tissue. Sensitizers that have been conjugated with cancerfinding moieties have high specificity for cancer tissue. 5662 His topathological studies posttreatment in mice affirm the fluorescence data. 4 
Activation
The energy source, ultrasound or light, is highly specific and focused. The specificity stems from the ability to turn the energy source on and off at will and focus just on targeted tissue. Ultrasound is approximately of the same frequency and intensity as diagnostic ultrasound, which is not harmful to healthy tissue. Because the ultrasound does not interact with tissue, 63,64(pp539559) it is able to penetrate deep into the body; thus, USAT is able to treat highly embedded tumors and those beneath the bone and the skull.
Tumor Debulking
Activated therapy creates an inflammatory response leading to metamorphic tissue and quickly to necrotic tissue. After an initial period of swelling (not tumor growth), tumors actually shrink and are reabsorbed to some degree. Thus, this treatment is not confined to small, superficial tumors.
Compatibility
Activated therapy can be used before or after surgery, che motherapy, and/or ionizing radiation therapy. None of these other therapies is compromised by activated therapy and, unlike these other treatments, can be repeated many times with no resistance developing, 65 minimal morbidity, and better functional results.
In this study, we present both LC 50 toxicity and cancer cell killing efficacy as determined in zebra fish. The zebra fish model organism is increasingly used for assessing drug toxic ity and safety, and numerous studies confirm that mammalian and zebra fish toxicity profiles are strikingly similar. 66 LC 50 studies on both SF1 and SF2 reveal that LC 50 is quite high and the substances have very low toxicity toward zebra fish. In the worst case, 5% zebra fish death is noted at the maximum soluble concentration of the sonosensitizer. In the efficacy studies, melanoma cell line WM2664, derived from a meta static site of a malignant melanoma was tested against SF1 and SF2. Both sonosensitizer systems showed marked effi cacy for the destruction of the melanoma cells. The cell killing capacity was a function of sonosensitizer concentration.
Materials and Methods Compounds
The compounds, SF1 and SF2, were separately preweighed, and 20 mM stock solution in fish water was prepared. The stock solutions were stored at 4°C before use. Fish water was used as carrier control.
Standard Procedures for Embryo Collection
Embryos were generated by natural pairwise mating, as described in the Zebrafish Handbook. 67 For each mating, 4 to 5 pairs of adult zebra fish were set up and, on average, 100 to 150 embryos per pair were generated. Embryos were maintained at 28°C in fish water (200 mg Instant Ocean Salt [Aquarium Systems, Mentor, OH] per liter of deion ized water; pH 6.67.0 maintained with 2.5 mg/L Jungle pH Stabilizer [Jungle Laboratories Corporation, Cibolo, TX]; conductivity 670760 mS). They were cleaned (dead emb ryos removed) and sorted by developmental stage 68 at 6 and 24 hours postfertilization (hpf). Because the embryo rec eives nourishment from an attached yolk sac, no feeding was required for 7 days postfertilization (dpf).
Compound Treatment for LC 50 Determination
We distributed 20 hpf zebra fish into 6well culture plates, 30 zebra fish per well in 100 mL of fish water. SF1 and SF2 were added to the fish water, and zebra fish were exposed by semistatic immersion for 28 hours. Untreated zebra fish were used as controls. Repeat sets of experiments were per formed; we used SF1 and SF2 at 100, 200, 300, 400, 500, 600, 750, 850, 1000, 1500, and 2000 mM. The concentra tion of 2000 mM is approximately the maximum soluble concentration for both SF1 and SF2.
Lethality Curves
Mortality was recorded at 48 hpf. Bestfit concentrationresponse curves were generated using MS EXCEL. Because the highest mortality observed was ~5%, LC 50 was not cal culated for either sensitizer.
Melanoma Cell Culture Conditions
Melanoma cell line WM2664, derived from a metastatic site of a malignant melanoma, was cultured in Eagles Mini mum Essential Medium (Invitrogen, Carlsbad, CA) at 37°C, supplemented with 10% fetal bovine serum (Hyclone, Logan, UT) and grown to approximately 80% confluence before harvesting for the cytotoxicity study.
Drug Treatment
We added 2 units/mL of dispase (Gibco) to the WM2664 culture flask and incubated it at 37°C for 30 minutes to achieve a single cell suspension, which was centrifuged at 2500 rpm for 5 minutes to recover a packed cell pellet.
The pellet was resuspended in the culture medium to obtain a density of ~5 × 10 6 cells/mL. Then, 100 mL (~5 × 10 5 cells) of the cell suspension was distributed to the wells of a 96well microplate; 10 mL of carrier or SF1 and SF2 solution, respectively, was added to each well, and incubation was performed at 37°C for 24 hours. We used 5 concentrations, one log apart-0.1, 1, 10, 100, and 1000 mM-to determine the concentration range that can cause cell death. Six wells were used for each concentration. The number of cells was determined by the CyQUANT cell pro liferation assay (see below).
Quantitation of Melanoma Cells Using CyQUANT Proliferation Assay
To quantify the total number of melanoma cells, we used CyQUANT dye, a welldeveloped reagent for quantifying cell numbers in cell culture (Molecular Probes, Eugene, OR). After drug treatment, we centrifuged the 96well culture plate to precipitate melanoma cells; the superna tant was carefully aspirated off; cells were lysed by freezing and thawing. After thawing, 200 mL of CyQUANT rea gent solution was then added to each well. The dye reacted with total nucleic acid to produce a soluble fluo rescent end product, which was measured at 480/520 nm (excitation/emission) within 2 to 5 minutes using a micro plate reader. A standard curve with known number of cells was set up for each experiment; the number of mela noma cells in the sample was calculated against standards. Because the linearity of the standard curve did not extend to 5 × 10 6 cells, we used the mean relative fluorescence unit (RFU) to calculate the drug effect, using the follow ing formula:
A dose-response curve was generated by plotting per cen tage cell death versus concentration; LC 50 for melanoma cyt otoxicity was calculated based on the dose-response curve.
Results

Determination of LC 50
LC 50 was estimated in repeated experiments: 20 hpf zebra fish were treated with sonosensitizers for 28 hours at 28°C at 100, 200, 300, 400, 500, 600, 750, 850, 1000, 1500, and 2000 mM. SF1. Lethality was not observed in any of the experi ments ( Table 1 ). The concentration-response curves were generated as shown in Figure 1 . No lethality was observed for SF1 at the highest soluble concentration (2000 mM), and 50% lethality was not reached; LC 50 was not determined.
SF2. Significant lethality was not observed in any of the experiments ( Table 2 ). The concentration-response curves were generated as shown in Figure 2 . The highest lethality observed for SF2 at the highest soluble concentration (2000 mM) was 5.0%; 50% lethality was not reached, and LC 50 was not determined.
Assessment of Cytotoxicity for Melanoma Cancer Cell Line WM-266-4
SF1 and SF2 each exhibited significant cytotoxic effects on human melanoma cancer cells WM2664 in vitro.
SF1 cytotoxicity for the melanoma cancer cell line WM2664 was assessed at 1, 10, 100, 1000, and 2000 81%, and 87% death, respectively, in the human mela noma cancer cell line WM2664 (Table 5, Figure 4 ). Based on the results, a dose-response curve was generated as shown in Figure 4 . The compound SF1 was found to be very toxic to the human melanoma cancer cell line WM2664. SF2 cytotoxicity for melanoma cancer cell WM2664 was assessed at 0.1, 1, 10, 100, and 1000 mM; 6 wells were mM; 6 wells were used for each concentration; mean cell number for each group was calculated based on the standard curves (Table 3, Figure 3 ) and was used to calculate drug effect; results are shown in Tables 4 and 5 . SF1 caused very significant (P < .0001 using 1way ANOVA) death in the human melanoma cancer cell line WM2664; Dun nett's test identified significant effect at 100, 1000, and 2000 mM concentrations (Table 4) , which caused 57%, Figure 5 ). Based on the results, a dose-response curve was generated as shown in Figure 5 . SF2 was found to be very toxic to the human melanoma cancer cell line WM2664.
Discussion
ACT is a treatment modality wherein a tuned energy source activates a preloaded sensitizer creating a cascade of cyto pathogenic endogenous agents. The primary modes of activation are PDT, whereby a photosensitizer is activated with light, and USAT, whereby a sonosensitizer is acti vated with ultrasound energy. A new class of dual activated sensitizers has been developed that are activated by either or both ultrasound and red light. When these agents are used in a treatment system, it is referred to as the Sonne Lux protocol. Activated therapy offers a potential attractive alternative over conventional therapies in several areas, including efficacy, breadth of tumor types treatable, quality of life, aesthetics, specificity, activation, tumor debulking, and compatibility with other therapies. USAT appears to fulfill the promises of PDT while avoid ing the inability of light to penetrate to deep tissue tumors. 69 The clear advantage of USAT over PDT is the ability to address the limited depth of light energy penetration to sen sitizer compounds and destroy deep tumors. This limitation is overcome when compounds can be sonoactivated by deep penetrating sonoenergy. The treatment is further enhanced with the use of dualactivation sensitizers such as SF1 or SF2 and both activation energy sources in a therapeutic mode referred to as the SonneLux protocol.
Indeed, there are emerging data that indicate that the dual fun ctioning agents provide greater treatment efficacy compared with a single mode of treatment. 70 The mechanism of PDT action is reasonably well understood, whereas that of USAT is less well characterized. The hypothesis on the enhanced used for each concentration. Mean fluorescence was used to calculate the drug effect. Results are shown in Tables 6 and 7 . SF2 caused very significant (P = .0001 using 1way ANOVA) tumor cell killing efficacy of the dualacting sensitizers is that, whereas PDT and USAT have overlapping mechanisms of action, there are also differences-for example, sonoporation. Critical to the success of activated therapy is the efficacy and safety of molecules that respond efficiently to ultra sound and light to produce targeted cytopathogenic moieties. In this study, we showed that both the dual functioning agents SF1 and SF2 have very low toxicity toward zebra fish. In addition, these sensitizers show significant toxicity toward the human melanoma cancer cells WM2664. A significant human study using the SonneLux protocol in a compassionate care mode on stage 4 cancer patients is being submitted for publication (Julian Kenyon, MD, Dove Clinic, private communication). Patients treated had not responded to or had had recurrent aggressive tumors when the standard suite of chemotherapy, radiotherapy, and sur gery was applied. This work covers 4 years of treatment history on 116 patients. The study reveals that the mean sur vival times are enhanced compared with those statistically expected. In addition, many patients continue to live well and productively beyond their expected mean survival times and are being reevaluated on a regular basis. This very important initial report shows that some of the hopes and expectations of ACT can be realized in the clinic.
Conclusions
There are increasing data showing that ACT is a promising new modality for cancer treatment. However, not much clinical data on ultrasound activation have been published. One reason is the difficulty in developing drugs suitable for clinical use. Recently, SF1 and SF2, new dual sensitizing agents activated both by light and ultrasound, have been developed by SonneMed LLC (Winchester, MA, USA). These agents have very high sonoactivity that is dependent on ultrasound energy intensity. 4 These agents also absorb red light at 636 nm creating a photodynamic effect.
In this study, the lethal toxicity toward embryonic cells and cytotoxicity toward human melanoma cancer cells WM2664 in vitro was examined. Our data reveal that SF1 and SF2 have very low apparent toxicity and are effective at destroying can cer cells in a concentration dependent manner. Considering the favorably low toxicity, the likely high therapeutic index, and cytotoxicity data, together with previous data on the inhi bition of mouse S180 sarcoma tumor growth, we con clude that ACT with SF1 and SF2 is probably safe and may have significant cytotoxic activity. ACT has great pro mise for clinical use for cancer treatment in the future.
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